Skip to main content

Prophylactic RBC transfusions in children with cancer: guideline

A clinical practice guideline providing recommendations on prophylactic red blood cell transfusions in children and neonates with cancer receiving treatment with curative intent.

Read more

Editor's Choice

Quitting smoking early after cancer diagnosis improves survival

A prospective cohort study has shown that quitting smoking after a cancer diagnosis is associated with improved survival, with the greatest benefit for those quitting within 6 months.

CAR T-cell therapy for CNS lymphoma

Neurotoxicity concerns have led to people with CNS lymphomas being excluded from pivotal trials of CAR T-cell therapies. But data from recent studies show promising efficacy and manageable toxicity.

CUP presenting with heart failure

Heart failure as an unusual first manifestation of carcinoma of unknown primary, highlighting that common clinical symptoms can reveal uncommon neoplastic etiologies.

Reducing the lymphedema risk in breast cancer

Evidence-based recommendations from an expert panel on risk reduction practices for people at risk for or with breast cancer-related lymphedema. Covering topics ranging from screening and patient education to considerations for exercise and air travel.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

At a glance: The KEYNOTE lung cancer trials

A quick guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in non-small-cell and small-cell lung cancer.

Developed by: Springer Medicine
Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version

Case Studies

CUP presenting with heart failure

Heart failure as an unusual first manifestation of carcinoma of unknown primary, highlighting that common clinical symptoms can reveal uncommon neoplastic etiologies.

Stroke as initial manifestation of CML progression

A patient with chronic myeloid leukemia presented with the signs and symptoms of acute ischemic stroke and was found on further evaluation to have progressed to the promyelocytic blast phase.

Tracheopericardial fistula masquerading as acute MI

Tracheopericardial fistula is often misdiagnosed due to its rarity and nonspecific presentation. In this patient with recurrent lung cancer, it was initially mistaken for an acute myocardial infarction.

Episode 9: The gut microbiome and CAR T-cell therapy

How do nutrition, supplements and antibiotics impact patient outcomes?

Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

Prof. Marion Subklewe
Listen now

Current Reviews

Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis

To synthesize the evidence on the efficacy and safety of teclistamab in treating relapsed/refractory multiple myeloma (RRMM). A systematic search for records published from inception until June 2024 was conducted on PubMed, Web of Science, EMBASE …

Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors

The optimal management of non-metastatic gastroesophageal (GE) junction tumors has been challenging to define, because anatomically the GE junction straddles two organs – the esophagus and stomach. Therefore, most randomized trials of both stomach …

The cGAS-STING pathway in HIV-1 and Mycobacterium tuberculosis coinfection

Mycobacterium tuberculosis (M. tuberculosis) infection is the most common opportunistic infection in human immunodeficiency virus-1 (HIV-1)-infected individuals, and the mutual reinforcement of these two pathogens may accelerate disease …

Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma

Neuroblastoma (NB) is the most common extracranial solid cancer in children. Despite intensive multimodality treatment, long-term survival of patients with high-risk NB, which comprises more than half of all cases, remains poor. Nuclear medicine …

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

  • Webinar | 19-02-2024 | 17:30 (CET)

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Watch now

CME & eLearning

SPONSORED

Webinar

1.5 European CME credits (ECMEC®s)

A series of patient cases underpin this interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.

Sponsored by:
  • Kyowa Kirin
Developed by: Springer Healthcare

Symposium (Link opens in a new window)

An independent symposium at the 10th COMy World Congress focusing on BCMA-targeting strategies for the treatment of multiple myeloma. Gain insights into the latest clinical data and the implications for clinical practice.

Supported by:
  • GlaxoSmithKline
Developed by: Springer Healthcare IME

eLearning (Link opens in a new window)

The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.

Supported by:
  • Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Developed by: Springer Healthcare IME

Further Reading

Racial/ethnic differences in risk factors for non-cardia gastric cancer: an analysis of the Multiethnic Cohort (MEC) Study

In 2023, it is estimated that there will be 26,500 new gastric cancer (GC) cases and 11,130 GC-related deaths in the United States (US) [ 1 ]. Unfortunately, only 28% of cases are expected to be diagnosed in localized stages when patients are …

Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan

Breast cancer is among the most common cancers affecting women worldwide. Japan has experienced a remarkable 51.1% increase from 2004 to 2010 [ 1 , 2 ]. Within this context, human epidermal growth factor receptor 2 (HER2)-positive breast cancer …

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort

Overall survival (OS) for patients with advanced or metastatic breast cancer (ABC) has improved over the past 20 years. However, median OS is still at less than four years in a large French subcohort with HR + HER2- ABC patients younger than 70 …

Related topics

CAR T-cell therapy for CNS lymphoma

Neurotoxicity concerns have led to people with CNS lymphomas being excluded from pivotal trials of CAR T-cell therapies. But data from recent studies show promising efficacy and manageable toxicity.

Read more

Prophylactic RBC transfusions in children with cancer: guideline

A clinical practice guideline providing recommendations on prophylactic red blood cell transfusions in children and neonates with cancer receiving treatment with curative intent.

Read more